Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Truvada + leuprolide
- Development stage
- Unknown
- Lead developer
- Johns Hopkins University
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Truvada + leuprolide is a combination of the fixed-dose antiretroviral Truvada (emtricitabine and tenofovir disoproxil fumarate) and the gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate. This combination is being studied by Johns Hopkins University in the 'PrEP-GAHT Interactions in TGW' Phase 1 clinical trial. The study aims to evaluate the pharmacokinetic and pharmacodynamic interactions between HIV pre-exposure prophylaxis (PrEP) and gender-affirming hormone therapy (GAHT) in transgender women. Truvada acts as a nucleoside/nucleotide reverse transcriptase inhibitor to prevent HIV infection, while leuprolide is used for testosterone suppression. The research focuses on optimizing PrEP dosing in the context of exogenous estrogen and testosterone suppression to ensure effective HIV prevention in this population.
- Brand names
- Lupron
- Other names
- TDF/FTC + leuprolidetenofovir disoproxil fumarate + emtricitabine + leuprolide
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseGnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on Truvada + leuprolide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Truvada + leuprolide.